Review



mouse anti dna rna hybrid antibody  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    ATCC mouse anti dna rna hybrid antibody
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Anti Dna Rna Hybrid Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 106 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/bio_rxiv__2025__09__30__678750-270-10-18?v=ATCC
    Average 95 stars, based on 106 article reviews
    mouse anti dna rna hybrid antibody - by Bioz Stars, 2026-07
    95/100 stars

    Images

    1) Product Images from "The 7SK small nuclear ribonucleoprotein links the cell responses to transcription and replication stress by promoting replication fork reversal and homologous recombination"

    Article Title: The 7SK small nuclear ribonucleoprotein links the cell responses to transcription and replication stress by promoting replication fork reversal and homologous recombination

    Journal: bioRxiv

    doi: 10.1101/2025.09.30.678750

    A) Schematic of active P-TEFb release from 7SK-snRNP to promote RNA polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to DNA fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Figure Legend Snippet: A) Schematic of active P-TEFb release from 7SK-snRNP to promote RNA polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to DNA fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.

    Techniques Used: Control, Transfection

    A) Protein levels of CDK9 in soluble extract (SE) and nuclear pellet (NP) fractions after 2 h treatment with 10 μM CPT or 200 μM HU +/- HEXIM1 siRNA (48 h). B) Protein levels of CDK9 in SE and nuclear NP fractions +/- LARP7 siRNA as in A. C) Relative levels of SE (7SK-snRNP bound) versus NP (chromatin-bound) P-TEFb after treatment +/- HEXIM1 siRNA as in A. n=3. D) Relative levels of SE versus NP P-TEFb after treatment +/- LARP7 siRNA as in B. n=3. E) Representative images of nascent RNA labelling with 5-ethynyluridine (EU). DNA was detected using DAPI. Bars: 50 μm. F) Nuclear EU intensities after treatment with 10 μM CPT and EU for 20 or 50 min. n=1. G) Nuclear EU intensities after treatment with 10 μM CPT or 200 μM HU (2 h) +/- HEXIM1 siRNA. n=3. H) Slot blots of genomic DNA stained with S9.6 antibody (RNA:DNA hybrids) and double-stranded DNA (dsDNA; loading control) after treatment with 10 μM CPT or 200 μM HU (20 min) +/- HEXIM1 siRNA. RNase H treatment was used as control. I) RNA:DNA hybrid quantification as in E. n=4. J) Replication fork speeds (IdU label) after CPT or HU treatment overexpression of turboGFP-RNase H1 (+) or eGFP vector control (-). Data from 2 repeats. K) Approach for siRNA depletion and 10 μM CPT or 200 μM HU treatment prior to immunostaining. L) Percentages of cells with >10 γH2AX foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=2-3. M) Percentages of cells with >9 53BP1 foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=3. Scatter blots show aggregates and medians (black points) of independent repeats with overall median (line). ANOVA or Kruskal-Wallis with multiple comparisons test, * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns: not significant.
    Figure Legend Snippet: A) Protein levels of CDK9 in soluble extract (SE) and nuclear pellet (NP) fractions after 2 h treatment with 10 μM CPT or 200 μM HU +/- HEXIM1 siRNA (48 h). B) Protein levels of CDK9 in SE and nuclear NP fractions +/- LARP7 siRNA as in A. C) Relative levels of SE (7SK-snRNP bound) versus NP (chromatin-bound) P-TEFb after treatment +/- HEXIM1 siRNA as in A. n=3. D) Relative levels of SE versus NP P-TEFb after treatment +/- LARP7 siRNA as in B. n=3. E) Representative images of nascent RNA labelling with 5-ethynyluridine (EU). DNA was detected using DAPI. Bars: 50 μm. F) Nuclear EU intensities after treatment with 10 μM CPT and EU for 20 or 50 min. n=1. G) Nuclear EU intensities after treatment with 10 μM CPT or 200 μM HU (2 h) +/- HEXIM1 siRNA. n=3. H) Slot blots of genomic DNA stained with S9.6 antibody (RNA:DNA hybrids) and double-stranded DNA (dsDNA; loading control) after treatment with 10 μM CPT or 200 μM HU (20 min) +/- HEXIM1 siRNA. RNase H treatment was used as control. I) RNA:DNA hybrid quantification as in E. n=4. J) Replication fork speeds (IdU label) after CPT or HU treatment overexpression of turboGFP-RNase H1 (+) or eGFP vector control (-). Data from 2 repeats. K) Approach for siRNA depletion and 10 μM CPT or 200 μM HU treatment prior to immunostaining. L) Percentages of cells with >10 γH2AX foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=2-3. M) Percentages of cells with >9 53BP1 foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=3. Scatter blots show aggregates and medians (black points) of independent repeats with overall median (line). ANOVA or Kruskal-Wallis with multiple comparisons test, * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns: not significant.

    Techniques Used: Staining, Control, Over Expression, Plasmid Preparation, Immunostaining



    Similar Products

    95
    ATCC mouse anti dna rna hybrid antibody
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Anti Dna Rna Hybrid Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/bio_rxiv__2025__09__30__678750-270-10-18?v=ATCC
    Average 95 stars, based on 1 article reviews
    mouse anti dna rna hybrid antibody - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    86
    Absolute Biotech Inc mouse dna rna hybrid s9 6
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Dna Rna Hybrid S9 6, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/pm40825050-320-43-47?v=Absolute+Biotech+Inc
    Average 86 stars, based on 1 article reviews
    mouse dna rna hybrid s9 6 - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    90
    Millipore mouse anti-dna–rna hybrid antibody, clone s9.6
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Anti Dna–Rna Hybrid Antibody, Clone S9.6, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/pmc12123415-117-51-52?v=Millipore
    Average 90 stars, based on 1 article reviews
    mouse anti-dna–rna hybrid antibody, clone s9.6 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Millipore mouse anti-dna-rna hybrid antibody, clone s9.6
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Anti Dna Rna Hybrid Antibody, Clone S9.6, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/pm40444635-99-53-54?v=Millipore
    Average 90 stars, based on 1 article reviews
    mouse anti-dna-rna hybrid antibody, clone s9.6 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Millipore mouse monoclonal anti-rna-dna hybrid (s9.6) antibody
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Monoclonal Anti Rna Dna Hybrid (S9.6) Antibody, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/pm39706185-330-16-22?v=Millipore
    Average 90 stars, based on 1 article reviews
    mouse monoclonal anti-rna-dna hybrid (s9.6) antibody - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Absolute Biotech Inc mouse anti- dna- rna hybrid s9.6
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Anti Dna Rna Hybrid S9.6, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/10__7554_slash_elife__97348-399-16-22?v=Absolute+Biotech+Inc
    Average 90 stars, based on 1 article reviews
    mouse anti- dna- rna hybrid s9.6 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Absolute Biotech Inc mouse anti-dna-rna hybrid s9.6
    A) Schematic of active P-TEFb release from 7SK-snRNP to promote <t>RNA</t> polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to <t>DNA</t> fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.
    Mouse Anti Dna Rna Hybrid S9.6, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+dna+rna+hybrid+antibody/pmc11616997-317-9-13?v=Absolute+Biotech+Inc
    Average 90 stars, based on 1 article reviews
    mouse anti-dna-rna hybrid s9.6 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    Image Search Results


    A) Schematic of active P-TEFb release from 7SK-snRNP to promote RNA polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to DNA fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.

    Journal: bioRxiv

    Article Title: The 7SK small nuclear ribonucleoprotein links the cell responses to transcription and replication stress by promoting replication fork reversal and homologous recombination

    doi: 10.1101/2025.09.30.678750

    Figure Lengend Snippet: A) Schematic of active P-TEFb release from 7SK-snRNP to promote RNA polymerase II (RNAPII) pause release in response to stress and growth stimuli. B) Protein levels of HEXIM1, LARP7 and Tubulin (loading control) in U2OS cells 48 h after siRNA transfection. nonT = non-targeting control siRNA. C) Approach for siRNA depletion or small molecule inhibitor treatment prior to DNA fibre labelling in presence of camptothecin (CPT, 10 μM) or hydroxyurea (HU, 200 μM). D) Replication fork speeds (IdU label) after CPT or HU treatment in presence of HEXIM1 (+) or nonT (-) siRNA. Data from 2 repeats. E) Replication fork speeds (IdU label) after CPT or HU treatment in presence of LARP7 (+) or nonT (-) siRNA. Data from 2-3 repeats. F) DRB inhibits P-TEFb and p38 MAPK inhibitor (P38i) inhibits 7SK-snRNP/P-TEFb dissociation. G) Replication fork speeds (IdU label) after CPT or HU treatment +/- p38i. Data from 3 repeats. H) Replication fork speeds (IdU label) after CPT or HU treatment +/- 100 μM DRB. Data from 2 repeats. I) Nascent chromatin capture proteomics in HeLa S3 cells shows limited enrichment or depletion of HEXIM1, LARP7 and MEPCE at ongoing (nascent/mature chromatin), stalled (3 mM HU, 30 min/untreated) or collapsed (1 μM CPT, 40 min + roscovinite/roscovitine) replication forks compared to PCNA or RAD51. Roscovitine was included to prevent new origin firing. Scatter graphs show aggregates and medians (black points) of independent repeats with overall median (line). Kruskal-Wallis with multiple comparisons test, **** p ≤ 0.0001; ns: not significant.

    Article Snippet: The membrane was then incubated overnight at 4 °C in mouse anti-DNA-RNA hybrid antibody (S9.6 hybridoma growth medium, ATCC HB-8730, 1:1,000) or mouse anti-dsDNA antibody (Abcam ab27156, 1:100,000) in sterile 5 % BSA/TBST, before being washed in TBST and incubated in goat anti-mouse HRP (Cell Signaling 7074, 1:5,000) 5 % milk/TBST for 1 hour at room temperature.

    Techniques: Control, Transfection

    A) Protein levels of CDK9 in soluble extract (SE) and nuclear pellet (NP) fractions after 2 h treatment with 10 μM CPT or 200 μM HU +/- HEXIM1 siRNA (48 h). B) Protein levels of CDK9 in SE and nuclear NP fractions +/- LARP7 siRNA as in A. C) Relative levels of SE (7SK-snRNP bound) versus NP (chromatin-bound) P-TEFb after treatment +/- HEXIM1 siRNA as in A. n=3. D) Relative levels of SE versus NP P-TEFb after treatment +/- LARP7 siRNA as in B. n=3. E) Representative images of nascent RNA labelling with 5-ethynyluridine (EU). DNA was detected using DAPI. Bars: 50 μm. F) Nuclear EU intensities after treatment with 10 μM CPT and EU for 20 or 50 min. n=1. G) Nuclear EU intensities after treatment with 10 μM CPT or 200 μM HU (2 h) +/- HEXIM1 siRNA. n=3. H) Slot blots of genomic DNA stained with S9.6 antibody (RNA:DNA hybrids) and double-stranded DNA (dsDNA; loading control) after treatment with 10 μM CPT or 200 μM HU (20 min) +/- HEXIM1 siRNA. RNase H treatment was used as control. I) RNA:DNA hybrid quantification as in E. n=4. J) Replication fork speeds (IdU label) after CPT or HU treatment overexpression of turboGFP-RNase H1 (+) or eGFP vector control (-). Data from 2 repeats. K) Approach for siRNA depletion and 10 μM CPT or 200 μM HU treatment prior to immunostaining. L) Percentages of cells with >10 γH2AX foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=2-3. M) Percentages of cells with >9 53BP1 foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=3. Scatter blots show aggregates and medians (black points) of independent repeats with overall median (line). ANOVA or Kruskal-Wallis with multiple comparisons test, * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns: not significant.

    Journal: bioRxiv

    Article Title: The 7SK small nuclear ribonucleoprotein links the cell responses to transcription and replication stress by promoting replication fork reversal and homologous recombination

    doi: 10.1101/2025.09.30.678750

    Figure Lengend Snippet: A) Protein levels of CDK9 in soluble extract (SE) and nuclear pellet (NP) fractions after 2 h treatment with 10 μM CPT or 200 μM HU +/- HEXIM1 siRNA (48 h). B) Protein levels of CDK9 in SE and nuclear NP fractions +/- LARP7 siRNA as in A. C) Relative levels of SE (7SK-snRNP bound) versus NP (chromatin-bound) P-TEFb after treatment +/- HEXIM1 siRNA as in A. n=3. D) Relative levels of SE versus NP P-TEFb after treatment +/- LARP7 siRNA as in B. n=3. E) Representative images of nascent RNA labelling with 5-ethynyluridine (EU). DNA was detected using DAPI. Bars: 50 μm. F) Nuclear EU intensities after treatment with 10 μM CPT and EU for 20 or 50 min. n=1. G) Nuclear EU intensities after treatment with 10 μM CPT or 200 μM HU (2 h) +/- HEXIM1 siRNA. n=3. H) Slot blots of genomic DNA stained with S9.6 antibody (RNA:DNA hybrids) and double-stranded DNA (dsDNA; loading control) after treatment with 10 μM CPT or 200 μM HU (20 min) +/- HEXIM1 siRNA. RNase H treatment was used as control. I) RNA:DNA hybrid quantification as in E. n=4. J) Replication fork speeds (IdU label) after CPT or HU treatment overexpression of turboGFP-RNase H1 (+) or eGFP vector control (-). Data from 2 repeats. K) Approach for siRNA depletion and 10 μM CPT or 200 μM HU treatment prior to immunostaining. L) Percentages of cells with >10 γH2AX foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=2-3. M) Percentages of cells with >9 53BP1 foci after 2 h CPT or HU +/- HEXIM1 siRNA. n=3. Scatter blots show aggregates and medians (black points) of independent repeats with overall median (line). ANOVA or Kruskal-Wallis with multiple comparisons test, * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns: not significant.

    Article Snippet: The membrane was then incubated overnight at 4 °C in mouse anti-DNA-RNA hybrid antibody (S9.6 hybridoma growth medium, ATCC HB-8730, 1:1,000) or mouse anti-dsDNA antibody (Abcam ab27156, 1:100,000) in sterile 5 % BSA/TBST, before being washed in TBST and incubated in goat anti-mouse HRP (Cell Signaling 7074, 1:5,000) 5 % milk/TBST for 1 hour at room temperature.

    Techniques: Staining, Control, Over Expression, Plasmid Preparation, Immunostaining